Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Pharming  /  Pharming in november dan toch scoren

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

  • 0,815 21 mei 2024 17:35
  • -0,020 (-2,40%) Dagrange 0,806 - 0,835
  • 6.299.432 Gem. (3M) 6,5M

Pharming in november dan toch scoren

3.056 Posts
Pagina: «« 1 ... 110 111 112 113 114 ... 153 »» | Laatste | Omlaag ↓
  2. [verwijderd] 22 november 2016 09:22
    quote:

    jurpsy schreef op 22 november 2016 09:10:

    [...]

    Men heeft de inkomsten van de claimemissie absoluut niet nodig om de deal te sluiten.
    Het afronden van de deal wordt verwacht rond 6/12.
    "De aankooptransactie zal worden afgerond zodra.....dit wordt verwacht vóórdat de claimemissie is afgerond."

    Uit het koeterwaals maak ik op dat de deal met Valeant afgerond wordt voor de afronding van de claim-emissie en dat is dus voor 6 december.
    Verder zullen die paar dagen verschil me overigens een biet wezen.
  3. jurpsy 22 november 2016 09:25
    quote:

    Beur schreef op 22 november 2016 09:22:

    [...]"De aankooptransactie zal worden afgerond.....vóórdat de claimemissie is afgerond."

    Uit het koeterwaals maak ik op dat de deal met Valeant afgerond wordt voor de afronding van de claim-emissie en dat is dus voor 6 december.
    Verder zullen die paar dagen verschil me overigens een biet wezen.

    zo is dat ;

    Pharming intends to use the net proceeds from the issue of all of the New Shares
    (expected to be €11.3 million), together with the net proceeds from the placement
    of the Convertible Bonds (expected to be approximately €53.9 million after costs of
    €8.1 million) and the net proceeds of the New Debt Facility (expected to be
    approximately €35.9 million after costs of €0.57 million and a retention for liquidity
    of €1.26 million), in total approximately €101 million, primarily for:
    • The payment of US$60 million (or €56.7 million) to Valeant as an upfront
    payment in respect of the acquisition by Pharming of all North American
    commercialisation rights to RUCONEST® (the Upfront Amount);
    • Repayment of the existing loan held with Oxford Finance LLC and Silicon Valley
    Bank, which will cost approximately €16.2 million (or $17.2 million);
    • Costs relating to the Transaction of approximately €0.7 million in total;
    • Financing the acceleration of sales efforts in respect of RUCONEST® in the USA
    including core marketing activities up to an amount of €20.0 million;
    • Financing the acceleration of sales efforts in respect of RUCONEST® in the EU
    including a modest expansion of commercial activity in the EU up to an amount
    of €7.0 million, following the addition of a further 21 countries to Pharming’s
    direct commercialisation territories after amendment of the Company’s
    distribution agreement with SOBI, and the introduction of self-administration
    home kits if the European Commission adopts the positive opinion issued on 11
    November 2016 by the Committee for Medicinal Products for Human Use and
    approves the use of such kits for RUCONEST®, including financing the
    acceleration of clinical investigation of new routes of administration for
    RUCONEST®, including specifically intramuscular and sub-cutaneous
    formulations; and
    • Any balance (expected to be approximately €0.5 million) will be used for general
    corporate purposes as appropriate.
    Closing of the New Debt Facility is conditional on a minimum raise of approximately
    €40 million (gross) between the Offer and the Convertible Bonds. The Management
    Board believes that based on the demand for Convertible Bonds it will be able both
    to trigger completion of the New Debt Facility and to close the Transaction.
    Consequently, there is no minimum amount required to be raised from the Rights
    Offer.
    Closing of the Transaction is expected shortly before 6 December 2016, and will be
    executed as soon as the Company has secured sufficient funds to do so. This may be
    before the closing of the Exercise Period, if the documentation for the Convertible
    Bonds can be completed before then. Apart from the condition that Pharming
    obtains sufficient financing for payment of the Upfront Amount, closing of the
    Transaction is subject to the following customary conditions (which may be waived
    by Pharming or Valeant to the extent legally permissible): no law or court order
    making the Transaction illegal or otherwise prohibiting the closing of the Transaction;
    execution or termination of certain agreements among Pharming and Valeant and
    the delivery of certain documents by Valeant to Pharming; no material adverse
    change regarding the assets or product subject to the Transaction; no breach by
    either party of representations and warranties or covenants provided for in the
    agreement with Valeant (subject to customary materiality qualifiers).
    In the event that the gross proceeds from the Convertible Bonds and the Offer
    together are less than €40 million and as a result the Transaction cannot close, the
    Debt Components and the Rump Offer will not be closed as well. It will not be
    possible, however, to reverse the closing of the Rights Offer and return the proceeds
    to the investors who have paid for the New Shares. In that case only, the net
    proceeds of the Rights Offer will be used for general corporate purposes and to
    extend the cash runway of the Company to 2019, including expenditure on the
    acceleration of sales of RUCONEST® in Europe and other territories and development
    of other new routes of administration for RUCONEST® such as intramuscular delivery
    and subcutaneous delivery, in addition to the roll-out of self-administration home
    kits for RUCONEST® in Europe.

    En nu de boer op met je bieten..

    suc6,

    jurps
  5. forum rang 10 DeZwarteRidder 22 november 2016 09:33
    • Financing the acceleration of sales efforts in respect of RUCONEST® in the EU including a modest expansion of commercial activity in the EU up to an amount of €7.0 million,

    Kun je nagaan wat de promotie in de USA gaat kosten.

    Ik heb het al vele malen gezegd: Zodra De Vries geld ter beschikking heeft, vliegt het de deur weer uit.

    Volgend jaar weer een emissie....??? lol
  6. jurpsy 22 november 2016 09:36
    quote:

    DeZwarteRidder schreef op 22 november 2016 09:33:

    • Financing the acceleration of sales efforts in respect of RUCONEST® in the EU including a modest expansion of commercial activity in the EU up to an amount of €7.0 million,

    Kun je nagaan wat de promotie in de USA gaat kosten.

    Ik heb het al vele malen gezegd: Zodra De Vries geld ter beschikking heeft, vliegt het de deur weer uit.

    Volgend jaar weer een emissie....??? lol
    .....je bent een ondernemer 'pur sang" ?
  8. [verwijderd] 22 november 2016 09:39
    quote:

    DeZwarteRidder schreef op 22 november 2016 09:33:

    • Financing the acceleration of sales efforts in respect of RUCONEST® in the EU including a modest expansion of commercial activity in the EU up to an amount of €7.0 million,

    Kun je nagaan wat de promotie in de USA gaat kosten.

    Financing the acceleration of sales efforts in respect of RUCONEST® in the USA including core marketing activities up to an amount of €20.0 million;
  10. forum rang 10 DeZwarteRidder 22 november 2016 09:43
    quote:

    Beur schreef op 22 november 2016 09:39:

    [...] Financing the acceleration of sales efforts in respect of RUCONEST® in the USA including core marketing activities up to an amount of €20.0 million;
    Dus in totaal gaan er binnenkort 27 miljoen de deur uit ALLEEN VOOR PROMOTIE EN MARKETING.

    Wie zei er ook weer dat Pharming binnenkort winst gaat maken....????

  11. [verwijderd] 22 november 2016 09:45
    quote:

    DeZwarteRidder schreef op 22 november 2016 09:43:

    [...]

    Dus in totaal gaan er binnenkort 27 miljoen de deur uit ALLEEN VOOR PROMOTIE EN MARKETING.

    Wie zei er ook weer dat Pharming binnenkort winst gaat maken....????

    promotie en marketing heb je nodig om een goeie sales (en dus inkomsten) te bewerkstelligen...

    als je dat niet begrijpt...tsja...
  12. [verwijderd] 22 november 2016 09:45
    quote:

    Beur schreef op 22 november 2016 09:39:

    [...] Financing the acceleration of sales efforts in respect of RUCONEST® in the USA including core marketing activities up to an amount of €20.0 million;
    Yep, en voor diegenen die dachten dat er op korte termijn iets te verwachten valt van prophylaxis de volgende quote uit de prospectus: "After having agreed the parameters for the ongoing clinical development of RUCONEST® in prophylaxis of HAE with the FDA, the Company expects that any further clinical development in this study program (Study 3201) will be completed by the end of 2018 at the latest, enabling a new application for a BLA with the FDA in prophylaxis to be filed soon after such studies are complete, assuming that the necessary endpoints are achieved." Dus geen enkele verwijzing naar een accelerated approval.
  13. forum rang 10 DeZwarteRidder 22 november 2016 09:47
    quote:

    moneymaker_BX schreef op 22 november 2016 09:32:

    Kan iemand eff kort uitleggen hoe het werkt
    Ik heb nu 1900 aandelen in mijn bezit
    wat gaat er gebeuren vanaf morgen
    en wat is slim te doen
    1) je kunt de claims verkopen als een soort 'dividend'.
    2) je kunt met de claims aandelen bijkopen.

    Wat is slim?

    Kop is verkopen en munt is bijkopen (of andersom).

  14. jurpsy 22 november 2016 09:47
    quote:

    AJ2016 schreef op 22 november 2016 09:45:

    [...]

    Yep, en voor diegenen die dachten dat er op korte termijn iets te verwachten valt van prophylaxis de volgende quote uit de prospectus: "After having agreed the parameters for the ongoing clinical development of RUCONEST® in prophylaxis of HAE with the FDA, the Company expects that any further clinical development in this study program (Study 3201) will be completed by the end of 2018 at the latest, enabling a new application for a BLA with the FDA in prophylaxis to be filed soon after such studies are complete, assuming that the necessary endpoints are achieved." Dus geen enkele verwijzing naar een accelerated approval.
    In November 2016, one of the Group’s principal competitors, Shire, announced to its patients and physicians
    that it is unable to supply its plasma-derived C1 inhibitor product Cinryze® for prophylaxis of HAE, because of
    a production issue at its supplier Sanquin in the Netherlands. This shortage of supply is expected by Shire to
    be rectified by early 2017. At the current time, RUCONEST® is the only alternate product with published data
    showing good efficacy in prophylaxis although it has not yet obtained approval for the indication in the USA,
    and it may be that some physicians feel it is a suitable alternative for patients unable to obtain their supply of
    Cinryze®. It is too early to say whether this will improve sales of RUCONEST® but this may be the outcome of
    this situation, in which case the financial and trading position of the Group would be improved.
  15. [verwijderd] 22 november 2016 09:49
    quote:

    AJ2016 schreef op 22 november 2016 09:45:

    [...]

    Yep, en voor diegenen die dachten dat er op korte termijn iets te verwachten valt van prophylaxis de volgende quote uit de prospectus: "After having agreed the parameters for the ongoing clinical development of RUCONEST® in prophylaxis of HAE with the FDA, the Company expects that any further clinical development in this study program (Study 3201) will be completed by the end of 2018 at the latest, enabling a new application for a BLA with the FDA in prophylaxis to be filed soon after such studies are complete, assuming that the necessary endpoints are achieved." Dus geen enkele verwijzing naar een accelerated approval.
    Laten we hopen dat men een bijzinnetje omtrent eventueel "slechts flankerend benodigd onderzoek" waarover De Vries repte, gewoon vergeten is ;)
  16. [verwijderd] 22 november 2016 09:50
    [i]"Closing of the New Debt Facility is conditional on a minimum raise of approximately €40 million (gross) between the Offer and the Convertible Bonds. The Management Board believes that based on the demand for Convertible Bonds it will be able both to trigger completion of the New Debt Facility and to close the Transaction. Consequently, there is no minimum amount required to be raised from the Rights Offer.
    Closing of the Transaction is expected shortly before 6 December 2016, and will be executed as soon as the Company has secured sufficient funds to do so." [/i]
  18. [verwijderd] 22 november 2016 09:53
    quote:

    jurpsy schreef op 22 november 2016 09:47:

    [...]

    In November 2016, one of the Group’s principal competitors, Shire, announced to its patients and physicians
    that it is unable to supply its plasma-derived C1 inhibitor product Cinryze® for prophylaxis of HAE, because of
    a production issue at its supplier Sanquin in the Netherlands. This shortage of supply is expected by Shire to
    be rectified by early 2017. At the current time, RUCONEST® is the only alternate product with published data
    showing good efficacy in prophylaxis although it has not yet obtained approval for the indication in the USA,
    and it may be that some physicians feel it is a suitable alternative for patients unable to obtain their supply of
    Cinryze®. It is too early to say whether this will improve sales of RUCONEST® but this may be the outcome of
    this situation, in which case the financial and trading position of the Group would be improved.
    Goed punt, maar dat is wat anders dan goedkeuring en zodra Cinryze weer beschikbaar is ebt eventuele omzet voor Ruconest op prophylaxis wel weer weg. Maar alle beetjes helpen, dat is zo. Anderzijds: de kosten van een volledige fase III zullen ongetwijfeld ook zeer omvangrijk zijn.
  19. forum rang 10 DeZwarteRidder 22 november 2016 09:55
    quote:

    AJ2016 schreef op 22 november 2016 09:45:

    [...]Yep, en voor diegenen die dachten dat er op korte termijn iets te verwachten valt van prophylaxis de volgende quote uit de prospectus: "After having agreed the parameters for the ongoing clinical development of RUCONEST® in prophylaxis of HAE with the FDA, the Company expects that any further clinical development in this study program (Study 3201) will be completed by the end of 2018 at the latest, enabling a new application for a BLA with the FDA in prophylaxis to be filed soon after such studies are complete, assuming that the necessary endpoints are achieved." Dus geen enkele verwijzing naar een accelerated approval.
    Tegen die tijd zijn er waarschijnlijk al 2 of 3 concurrenten op de markt en is Pharming weer te laat.
  20. jurpsy 22 november 2016 09:55
    Financing the acceleration of sales efforts in respect of RUCONEST® in the USA including the following core marketing activities up to an amount of €20.0 million including the following activity:

    o strengthening of medical science liaison activities, and the addition of extra sales representatives to
    complement the existing team who have very large areas to cover at present;
    o unconditional support for the HAEA, the HAE patients’ association in the USA, and for the
    University of California San Diego’s HAE Center of Excellence and other centres of excellence. This
    is necessary to enable proper support of HAE patients with difficulties in insurance, treatment or
    disease state, and must be unconditional to comply with all relevant legislation for both the
    Company and the various recipients including the Sunshine Act; and
    o additional activities to involve Key Opinion Leaders in HAE with RUCONEST® and its relative merits
    and benefits for patients, including help with development of new dosage forms. As with assistance
    for the patients’ association and related bodies, these activities are carefully planned to conform
    with the spirit and the word of all relevant legislation including the Sunshine Act, and may include
    non-product-specific speaking opportunities, advisory positions and product-neutral research,
    none of which may offer an inducement to a physician to prescribe or a patient to choose any
    Pharming product.
    • Financing the acceleration of sales efforts in respect of RUCONEST® in the EU including a modest
    expansion of commercial activity in the EU up to an amount of €7.0 million, following the addition of a
    further 21 countries to Pharming’s direct commercialisation territories after amendment of the
    Company’s distribution agreement with SOBI, and the introduction of self-administration home kits if the
    European Commission adopts the positive opinion issued on 11 November 2016 by the Committee for
    Medicinal Products for Human Use (CHMP) and approves the use of such kits for RUCONEST®, including
    financing the acceleration of clinical investigation of new routes of administration for RUCONEST®,
    including specifically intramuscular and sub-cutaneous formulations; and
    • Any balance (expected to be approximately €0.5 million) will be used for general corporate purposes as
    appropriate.
    Pharming intends to use its existing cash resources and cash derived from operations to service its existing
    research and development costs and the costs of the Debt Components.
3.056 Posts
Pagina: «« 1 ... 110 111 112 113 114 ... 153 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Markt lijkt groeipotentieel Pharming te onderschatten

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. 17:43 Jaarvergadering Pharming akkoord met alle agendapunten
  2. 10 mei RBC verlaagt koersdoel Pharming
  3. 08 mei Update: Flinke omzetstijging Pharming 2
  4. 08 mei AEX houdt 900 punten waarschijnlijk niet vast, zorgen Ahold, Pharming en SBM voor spektakel? 2
  5. 19 apr Pharming lost voor 123 miljoen euro aan obligaties af
  6. 18 apr Pharming rondt plaatsing obligaties af 5
  7. 18 apr Pharming vervangt converteerbare lening 6
  8. 08 apr Pharming rondt rekrutering voor klinische studie leniolisib met kinderen af
  9. 14 mrt CEO: Pharming haalt omzet uit steeds meer landen 2
  10. 14 mrt Lichte plus voor AEX voorzien; zullen Pharming en Basic-Fit de boel opschudden?

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!